

Status: Currently Official on 17-Feb-2025
 Official Date: Official as of 01-May-2020
 Document Type: USP Monographs
 DocId: GUID-A29CD5A4-7F35-4BE5-AE49-19B3CFC483D4_4_en-US
 DOI: https://doi.org/10.31003/USPNF_M3960_04_01
 DOI Ref: oz8kl

© 2025 USPC
 Do not distribute

Amobarbital Sodium for Injection

DEFINITION

Amobarbital Sodium for Injection is Amobarbital Sodium suitable for parenteral use. It contains NLT 98.5% and NMT 100.5% of the labeled amount of amobarbital sodium ($C_{11}H_{17}N_2NaO_3$), calculated on the dried basis.

IDENTIFICATION

Change to read:

- **A.** [▲ SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197K](#)▲ (CN 1-MAY-2020)

Sample: Residue obtained in the Assay

Acceptance criteria: Meets the requirements

- **B.** [IDENTIFICATION TESTS—GENERAL, Sodium \(191\)](#).

Sample: Nominally 200 mg of amobarbital sodium from Amobarbital Sodium for Injection

Analysis: Ignite the *Sample*.

Acceptance criteria: The residue effervesces with acid and meets the requirements of the tests.

ASSAY

• PROCEDURE

Sample solution: Transfer nominally 500 mg of amobarbital sodium from Amobarbital Sodium for Injection to a suitable separator, and dissolve in 15 mL of water. Add 2 mL of hydrochloric acid, and shake. Completely extract the amobarbital with 25-mL portions of chloroform. Combine the chloroform extractions, and pass through a glass filter funnel into a tared beaker. Wash the separator and the filter with several small portions of chloroform. Use the combined chloroform extractions and the washings.

Test for completeness of extraction: Extract the remaining solution in the separator with an additional 10-mL portion of chloroform, and evaporate the solvent; NMT 0.5 mg of residue remains.

Analysis: Evaporate the *Sample solution* on a steam bath with the aid of a current of air. Dry the residue at 105° for 30 min, cool, and weigh. Calculate the percentage of the labeled amount of amobarbital sodium ($C_{11}H_{17}N_2NaO_3$) in the portion of Amobarbital Sodium for Injection taken:

$$\text{Result} = (W_R/W_S) \times (M_{r1}/M_{r2}) \times 100$$

W_R = weight of the residue from the *Analysis* (mg)

W_S = nominal weight of amobarbital sodium in the *Sample solution* (mg)

M_{r1} = molecular weight of amobarbital sodium, 248.25

M_{r2} = molecular weight of amobarbital, 226.27

Acceptance criteria: 98.5%–100.5% on the dried basis

PERFORMANCE TESTS

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meets the requirements

SPECIFIC TESTS

- [INJECTIONS AND IMPLANTED DRUG PRODUCTS \(1\), Specific Tests, Completeness and clarity of solutions](#): At the time of use, it meets the requirements.

- [COMPLETENESS OF SOLUTION \(641\)](#).

Sample solution: 1 g of amobarbital sodium from Amobarbital Sodium for Injection in 10 mL of carbon dioxide-free water

Acceptance criteria: After 1 min, the solution is clear and free from undissolved solid.

- [LOSS ON DRYING \(731\)](#).

Sample: 1 g

Analysis: Dry the *Sample* at 105° for 4 h.

Acceptance criteria: NMT 1.0%

- [pH \(791\)](#).

Sample solution: Nominally 100 mg/mL of amobarbital sodium from Amobarbital Sodium for Injection in carbon dioxide-free water

Acceptance criteria: NMT 11.0

- **STERILITY TESTS (71):** Meets the requirements
- **BACTERIAL ENDOTOXINS TEST (85):** It contains NMT 0.4 USP Endotoxin Units/mg of amobarbital sodium.
- **OTHER REQUIREMENTS:** It meets the requirements in [Labeling \(7\)](#), [Labels and Labeling for Injectable Products](#).

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve as described in [Packaging and Storage Requirements \(659\)](#), [Injection Packaging](#), [Packaging for constitution](#).
- **USP REFERENCE STANDARDS (11):**
[USP Amobarbital RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
AMOBARBITAL SODIUM FOR INJECTION	Documentary Standards Support	SM42020 Small Molecules 4
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM42020 Small Molecules 4

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 40(2)

Current DocID: GUID-A29CD5A4-7F35-4BE5-AE49-19B3CFC483D4_4_en-US

DOI: https://doi.org/10.31003/USPNF_M3960_04_01

DOI ref: [oz8kl](#)

OFFICIAL